- Home
- TBBK vs ZLAB Comparison
TBBK vs ZLAB Comparison
Compare TBBK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- ZLAB
- Stock Information
- Founded
- TBBK 1999
- ZLAB 2013
- Country
- TBBK United States
- ZLAB China
- Employees
- TBBK N/A
- ZLAB N/A
- Industry
- TBBK Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- ZLAB Health Care
- Exchange
- TBBK Nasdaq
- ZLAB Nasdaq
- Market Cap
- TBBK 2.7B
- ZLAB 1.8B
- IPO Year
- TBBK 2004
- ZLAB 2017
- Fundamental
- Price
- TBBK $50.51
- ZLAB $31.38
- Analyst Decision
- TBBK Buy
- ZLAB Strong Buy
- Analyst Count
- TBBK 3
- ZLAB 4
- Target Price
- TBBK $55.00
- ZLAB $52.50
- AVG Volume (30 Days)
- TBBK 564.7K
- ZLAB 976.3K
- Earning Date
- TBBK 10-24-2024
- ZLAB 11-12-2024
- Dividend Yield
- TBBK N/A
- ZLAB N/A
- EPS Growth
- TBBK 16.52
- ZLAB N/A
- EPS
- TBBK 3.95
- ZLAB N/A
- Revenue
- TBBK $472,015,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- TBBK N/A
- ZLAB $48.34
- Revenue Next Year
- TBBK $7.05
- ZLAB $47.12
- P/E Ratio
- TBBK $12.71
- ZLAB N/A
- Revenue Growth
- TBBK 6.71
- ZLAB 28.16
- 52 Week Low
- TBBK $29.92
- ZLAB $13.48
- 52 Week High
- TBBK $59.26
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- TBBK 44.27
- ZLAB 70.41
- Support Level
- TBBK $45.82
- ZLAB $31.52
- Resistance Level
- TBBK $59.26
- ZLAB $36.60
- Average True Range (ATR)
- TBBK 2.17
- ZLAB 1.36
- MACD
- TBBK -0.96
- ZLAB 0.34
- Stochastic Oscillator
- TBBK 35.86
- ZLAB 58.60
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.